Emerging Drug Profile (EDP) Leukemia and Lymphoma

Leukemia and Lymphoma

Read more about EDP and start exploring for free today here

Decoding of the six billion bases of the human genome not only provided fundamental knowledge of the complete genetic sequence of a normal cell, but also opened access to the capacity to compare anomalies in the cancer genome with its healthy counterpart, providing insights into the molecular underpinnings of the disease. While it is challenging to determine whether the revealed aberrations are in fact causal or driver(s) of the disease, they provide a potential therapeutic target and have had a transformative impact that became the basis of personalized and tumor-specific medicine. For hematological malignancies, these advances are moving at an exponential rate…

Rationale for the Emerging Drug Profile (EDP) feature in the journal

The knowledge of cellular processes at a molecular level continues to provide unprecedented opportunities for rational approaches to the design of therapeutics that are targeted at the cause of disease. Fueled by an increasingly detailed understanding of the human genome and the development of remarkable technological advances, it is clear that the era of personalized medicine has truly arrived. While sequencing of an individual patient's tumor genetic make-up is at its infancy, is expensive, has error rates and is time consuming (especially complex analyses of daunting data to obtain meaningful and applicable endpoints), attempts to utilize available knowledge of identified lesions in therapeutics is exponentially ongoing. During the last decade an unprecedented number of new drugs have been tested for hematological malignancies, and several innovative agents and strategies have become standard of care for leukemias, lymphomas and myeloma…

All EDP articles are free to access for 6 months and are marked with 'Emerging Drug Profile:'

Read more about EDP and start exploring for free today here